Evidence map›Paper›PMID 39560812›Full record

ArticleMetabolic brain disease2024

The SGLT2 inhibitor empagliflozin exerts neuroprotective effect against hydrogen peroxide-induced toxicity on primary neurons.

Athena S Davri, Andreas P Katsenos, Guzal K Tulyaganova, Nikolaos P Tzavellas, Yannis V Simos, Foivos S Kanellos, Spyridon Konitsiotis, Evangelia Dounousi, Konstantina Niaka, Sofia Bellou and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolic brain disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Athena S Davri *Laboratory of Physiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, 45110, Greece.ORCID 0000-0002-2818-8004
Andreas P Katsenos *Laboratory of Physiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, 45110, Greece.ORCID 0000-0002-4994-6708
Guzal K TulyaganovaLaboratory of Physiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, 45110, Greece.ORCID 0009-0001-4201-5898
Nikolaos P TzavellasLaboratory of Physiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, 45110, Greece.ORCID 0009-0000-4182-7627
Yannis V SimosLaboratory of Physiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, 45110, Greece.ORCID 0000-0003-1764-8906
Foivos S KanellosLaboratory of Physiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, 45110, Greece.ORCID 0000-0002-5373-6236
Spyridon KonitsiotisDepartment of Neurology, Faculty of Medicine, School of Health Sciences, University Hospital of Ioannina, Ioannina, 45110, Greece.ORCID 0000-0002-5217-1317
Evangelia DounousiDepartment of Nephrology, Faculty of Medicine, School of Health Sciences, Dialysis Center, University of Ιoannina, Nephroxenia Ioannina, Ioannina, 45110, Greece.ORCID 0000-0002-1172-1829
Konstantina NiakaDepartment of Biological Applications and Technology, School of Health Sciences, Institute of Biosciences, University Research Centre, University of Ioannina, Ioannina, 45110, Greece.
Sofia BellouBiomedical Research Institute, University of Ioannina Network of Research Supporting Laboratories (NRSL) Confocal Laser Scanning Microscopy Unit and Foundation for Research & Technology-Hellas, University Campus, Ioannina, 45110, Greece.ORCID 0000-0002-2124-6857
Panagiotis LekkasLaboratory of Physiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, 45110, Greece.ORCID 0000-0002-2285-0060
Chryssa BekiariLaboratory of Anatomy, Histology & Embryology, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece.ORCID 0000-0003-0600-3889
Anna BatistatouDepartment of Pathology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, 45110, Greece.ORCID 0000-0003-4353-9535
Dimitrios PeschosLaboratory of Physiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, 45110, Greece.ORCID 0000-0002-5490-0755
Konstantinos I TsamisLaboratory of Physiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, 45110, Greece. ktsamis@uoi.gr.ORCID 0000-0002-7032-1630

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxidative stress has been implicated in several chronic pathological conditions, leading to cell death and injury. Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) have several overlapping mechanisms as they are both characterized by increased oxidative stress, inflammation, insulin resistance, and autophagy dysfunction. The objective of this study was to elucidate the possible neuroprotective effect of empagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), against hydrogen peroxide-induced neurotoxicity in primary hippocampal neurons derived from wild-type (WT) and transgenic AD rats (TgF344-AD). An in vitro oxidative stress model was established using hydrogen peroxide to induce damage to neurons. Empagliflozin pretreatment was tested on this model initially through a cell viability assay. Flow cytometry and cell sorting were employed to discriminate the apoptotic and necrotic neuronal cell populations. Finally, the morphological and morphometric features of the neurons, including dendritic length and spine density, were evaluated using the SNT ImageJ plug-in following immunostaining with GFP. Sholl analysis was used to evaluate the impact of empagliflozin and hydrogen peroxide on dendritic arborization. Empagliflozin tended to ameliorate hydrogen peroxide-induced toxicity in primary neurons derived from WT rats and led to the preservation of dendritic spine density in both WT and TgF344-AD neurons (one-way ANOVA, p < 0.05). A modest improvement in dendrites' length was also observed. Empagliflozin pretreatment can partially mitigate dendritic and spine alterations induced by hydrogen peroxide in primary neurons. These results underscore the impact of empagliflozin on neuronal morphology and highlight its potential as a candidate for the treatment and/or prevention of AD.

Indexed as

Benzhydryl CompoundsGlucosidesHydrogen PeroxideNeuronsNeuroprotective AgentsSodium-Glucose Transporter 2 InhibitorsAnimalsCells, CulturedCell SurvivalHippocampusOxidative StressRatsRats, TransgenicBenzhydryl CompoundsempagliflozinGlucosidesHydrogen PeroxideNeuroprotective AgentsSodium-Glucose Transporter 2 InhibitorsAlzheimer’s diseaseEmpagliflozinNeuroprotectionOxidative stressSGLT2Type 2 diabetes mellitus

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.